Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026

Loading news article.

Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026 | WAPE

Immunocore Holdings Announces Achievement Of Target Patient Enrollment In TEBE-AM Clinical Trial; Topline Overall Survival Data Expected As Early As End Of 2026

Article summary

Related companies

Comments —